Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Daniel E. Johnson, Rachel A. O’Keefe, Jennifer R. Grandis
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 4, pp. 234-248
Open Access | Times Cited: 2301

Showing 1-25 of 2301 citing articles:

Head and neck squamous cell carcinoma
Daniel E. Johnson, Barbara Burtness, C. René Leemans, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 2775
Dendritic cells in cancer immunology and immunotherapy
Stefanie K. Wculek, Francisco J. Cueto, Adriana M. Mujal, et al.
Nature reviews. Immunology (2019) Vol. 20, Iss. 1, pp. 7-24
Closed Access | Times Cited: 1973
Targeting apoptosis in cancer therapy
Benedito A. Carneiro, Wafik S. El‐Deiry
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 7, pp. 395-417
Open Access | Times Cited: 1894
Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
Chi Zhang, Zhao Wu, Jiawen Li, et al.
International Journal of Antimicrobial Agents (2020) Vol. 55, Iss. 5, pp. 105954-105954
Open Access | Times Cited: 1751
Inflammation and tumor progression: signaling pathways and targeted intervention
Huakan Zhao, Lei Wu, Guifang Yan, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1599
Turning foes to friends: targeting cancer-associated fibroblasts
Xueman Chen, Erwei Song
Nature Reviews Drug Discovery (2018) Vol. 18, Iss. 2, pp. 99-115
Closed Access | Times Cited: 1405
Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives
Xiaoqi Mao, Jin Xu, Wei Wang, et al.
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 1390
Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer
Simon A. Jones, Brendan J. Jenkins
Nature reviews. Immunology (2018) Vol. 18, Iss. 12, pp. 773-789
Closed Access | Times Cited: 867
IL-6 in inflammation, autoimmunity and cancer
Toshio Hirano
International Immunology (2020) Vol. 33, Iss. 3, pp. 127-148
Open Access | Times Cited: 865
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Bingwen Liu, Min Li, Zhiguang Zhou, et al.
Journal of Autoimmunity (2020) Vol. 111, pp. 102452-102452
Open Access | Times Cited: 760
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
Tongyan Liu, Chencheng Han, Siwei Wang, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 705
Targeting STAT3 in Cancer Immunotherapy
Sailan Zou, Qiyu Tong, Bowen Liu, et al.
Molecular Cancer (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 704
Harnessing cytokines and chemokines for cancer therapy
David Propper, Frances R. Balkwill
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 4, pp. 237-253
Closed Access | Times Cited: 593
The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment
Lea Monteran, Neta Erez
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 554
Interleukins in cancer: from biology to therapy
Daria Briukhovetska, Janina Dörr, Stefan Endres, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 8, pp. 481-499
Open Access | Times Cited: 537
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Longchuan Bai, Haibin Zhou, Renqi Xu, et al.
Cancer Cell (2019) Vol. 36, Iss. 5, pp. 498-511.e17
Open Access | Times Cited: 483
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
Azucena Salas, Cristian Hernández-Rocha, Marjolijn Duijvestein, et al.
Nature Reviews Gastroenterology & Hepatology (2020) Vol. 17, Iss. 6, pp. 323-337
Closed Access | Times Cited: 464
COVID-19 infection: an overview on cytokine storm and related interventions
Soheila Montazersaheb, Seyed Mahdi Hosseiniyan Khatibi, Mohammad Saeid Hejazi, et al.
Virology Journal (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 455
Therapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map
Jennifer Huynh, Ashwini L. Chand, Daniel J. Gough, et al.
Nature reviews. Cancer (2018) Vol. 19, Iss. 2, pp. 82-96
Closed Access | Times Cited: 444
Lactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cells
Jia Xiong, Jia He, Jun Zhu, et al.
Molecular Cell (2022) Vol. 82, Iss. 9, pp. 1660-1677.e10
Open Access | Times Cited: 396
Mechanisms regulating PD-L1 expression on tumor and immune cells
Shuming Chen, George A. Crabill, Theresa S. Pritchard, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 369
Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host
Marlies Meisel, Reinhard Hinterleitner, Alain Pacis, et al.
Nature (2018) Vol. 557, Iss. 7706, pp. 580-584
Open Access | Times Cited: 343
The immunology of renal cell carcinoma
C. Marcela Díaz‐Montero, Brian I. Rini, James H. Finke
Nature Reviews Nephrology (2020) Vol. 16, Iss. 12, pp. 721-735
Closed Access | Times Cited: 343
Beyond immune checkpoint blockade: emerging immunological strategies
Shawn P. Kubli, Thorsten Berger, Daniel Vilarim Araújo, et al.
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 12, pp. 899-919
Closed Access | Times Cited: 339
Stem cell programs in cancer initiation, progression, and therapy resistance
Tianzhi Huang, Xiao Song, Dandan Xu, et al.
Theranostics (2020) Vol. 10, Iss. 19, pp. 8721-8743
Open Access | Times Cited: 333
Page 1 - Next Page

Scroll to top